


PROGRAM

Rheumatology Workshop for Spondyloarthritis



17 of May 2024



Hilton Nicosia



Επιστημονική Ρευματολογική Εταιρεία Κύπρου
Scientific Rheumatology Association of Cyprus

Under the
auspices of:



The Workshop has been accredited by CMA for 3 CME credit hours

SPEAKER



Xenofon Baraliakos, MD

Prof. Xenofon Baraliakos is the Head of Rheumatology at the Rheumazentrum Ruhrgebiet Herne and Professor for Internal Medicine and Rheumatology at the Ruhr-University Bochum, Germany.

He studied Human Medicine at the universities of Magdeburg and Berlin, Germany and received his PhD degree in 2005 with the first study on the MRI outcomes of patients with ankylosing spondylitis before and after therapy with monoclonal antibodies against TNF- α .

Prof. Baraliakos received his official Board Degrees in orthopaedic surgery in 2007 and in Internal Medicine and Rheumatology in 2014. His research interests include clinical and academic research in the field of spondyloarthritis, with special emphasis on imaging outcomes and treatment of the disease.

Among others, Dr Baraliakos won the EWRR Award, in 2005, the EULAR Young Investigator Award, in 2006 and 2008, the German patient's AS Society Award in 2010 and the 2014 Award for Excellence in Clinical Research from the European Society for Clinical Investigations.

Dr Baraliakos is the current President of ASAS (Assessment of Spondyloarthritis International Society) and President-Elect of EULAR (European Alliance of Associations for Rheumatology). He has served as Chair of the EULAR standing committee for musculoskeletal imaging. He holds membership of the American College of Rheumatology (ACR), the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the German Society of Rheumatology. He also acts as a reviewer and is an Associate Editor in a number of major rheumatological journals.

PROGRAM

Rheumatology
Workshop for
Spondyloarthritis



17 of May 2024

Dionysus Meeting Room

08:30 – 09:00 ● Registrations

09:00 – 09:10 ● Opening Remarks from the President of the Cyprus Rheumatology Society,
Dr. Stellina Chrysostomou

09:10 – 11:00 Plenary Lecture 1
**Clinical aspects of diagnosis and differential diagnosis of axSpA
& axial PsA – Role of inflammatory back pain and other clinical measures**

Plenary Lecture 2
Basics behind imaging in axSpA

Plenary Lecture 3
X-ray for axSpA

11:00 – 11:30 ● Coffee Break

Sponsored by  **NOVARTIS**

11:30 – 13:00 Plenary Lecture 4
Musculoskeletal MRI – introduction on different MRI sequences

Plenary Lecture 5
ASAS Definition – Detailed description on relevant structures

13:00 – 14:00 ● Lunch Break

14:00 – 17:00 Imaging Workshop on computers (Case reviews)

1. Clinical data (history exam) – participants to decide on pretest probability of axSpA

2. Present bloods including B27, CRP, ESR – modify probability

15:30 – 16:00 ● Coffee Break

3. Review SIJ Xray, MRI, CTs

4. Small group discussion and share-back

5. Final diagnosis and case summary

17:00 – 17:15 ● Q&A and closing remarks

19:00 ● Early Dinner

SPONSORS

Rheumatology
Workshop for
Spondyloarthritis



VHP HADJIPANAYIS



Lilly



Για την περιληψη χαρακτηριστικών
του Tremfya σαρώστε



Για την περιληψη χαρακτηριστικών
του Stelara σαρώστε



Διάθεση προϊόντων: προϊόντα που χορηγούνται με ιατρική συνταγή
Προϊόντα που αποζημιώνονται από τον Οργανισμό Ασφάλισης Υγείας

ΟΝΟΜΑ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ	ΣΥΣΚΕΥΑΣΙΑ	ΔΡΑΣΤΙΚΟ ΣΥΣΤΑΤΙΚΟ	Μέγιστη Δυνατή Λιανική Τιμή
STELARA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 90MG/PEN	1ML	USTEKINUMAB	2873.27
STELARA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 45MG/PEN	0.5ML	USTEKINUMAB	2814.89
STELARA CONCENTRATE FOR SOLUTION FOR INFUSION 130MG/VIAL	130MG	USTEKINUMAB	2873.27
TREMFYA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100MG/ML	1ML	GUSELKUMAB	2098.43

Αντιπρόσωπος στην Κύπρο

VHPHADJIPANAYIS

Λεωφόρος Γιάννου Κρανιώτη 236, 2334 Λατσιά, Λευκωσία, Κύπρος
Τηλ: 00357 22207700, Φαξ: 00357 22207748

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Κάτοχος άδειας κυκλοφορίας

Janssen
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson



XELJANZ®

[tofacitinib citrate]
5 mg tablets

Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.



Pfizer Ελλάς Α.Ε.
Λ. Μεσογείων 243, Ν. Ψυχικό 15451, Αθήνα, Ελλάδα,
Τηλ. Επικοινωνίας 210-6785800,
Αριθ. Γ.Ε.ΜΗ. 000242901000
Pfizer Ελλάς Α.Ε. (Cyprus Branch)
Λεωφόρος Αθαλάσσης 26, 2018 Λευκωσία, Κύπρος,
Τηλ: 22817690

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»